DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for cherubism — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCherubism maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for cherubism is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
SH3 domain binding protein 2 (SH3BP2) — SH3BP2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet pe8drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3TWR · 1.55 Å · ligand 3,6,9,12,15,18,21-HEPTAOXATRICOSANE-1,23-DIOL (PE8). Experimental structure, not a prediction.
What the evidence adds up to
Cherubism is a rare congenital condition that causes malformation of the jaw, appearing before age five and often regressing spontaneously after puberty. The disease can lead to enlargement of the jaw bone, tooth displacement, facial disfigurement, and psychological trauma. A 2010 case report of a 13-year-old girl with bilateral symmetrical mandibular enlargement describes fine needle aspiration cytology findings of moderate cellularity with spindle cells mixed with multinucleated giant cells of the osteoclast type, noting that giant cell containing soft tissue and bone lesions are part of the differential diagnosis.
There are no established management guidelines for cherubism. Conservative observation is typically favoured because of the possibility of spontaneous regression after puberty. A 2022 case series of three patients with moderate to severe cherubism reports early surgical intervention using curettage, osteotomy, and bony repositioning. The authors state the aim was to show the feasibility and safety of this minimally invasive technique to improve quality of life, aesthetics, and function, and possibly reduce the need for later reconstructive surgery. No quantitative outcomes such as survival, response rates, or sample sizes beyond three patients are provided.
The 2010 cytology report emphasises that with clinicoradiologic correlation, a specific diagnosis can be offered for a definitive therapeutic approach. A 2009 abstract, despite its title referring to a pancreatic cancer cell line, notes that cherubism is clinically well-characterised and that radiographic examination is essential, with histopathological examination complementary, and that genetic tests should now be used for final diagnosis.
What is still missing are large prospective studies, standardised outcome measures, and any pharmacological treatment data. No drug therapy is mentioned in any of these abstracts. The evidence base consists of small case series and single case reports, with no randomised trials, no controlled comparisons, and no validated patient stratification tools to predict which cases will regress and which will require intervention. Funding for multi-centre registries or trials of surgical versus conservative management is absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Natural Science Biology and Medicine · 2014 · 13 citations · open access
Cherubism: A rare case report
AbstractCherubism is a rare congenital disease resulting in malformation of the jaw. It occurs before the age of 5 years and regress spontaneously after puberty. It can result into enlargement of the jaw bone, tooth displacement, facial disfigurement and psychological trauma to patient. Hence, the understanding about the condition, its progression and management is necessary.
Plastic & Reconstructive Surgery Global Open · 2022 · 6 citations · open access
Severe Cherubism Treated with Curettage, Osteotomy, and Bony Repositioning: A Case Series of Three Patients
AbstractCherubism is a rare, autosomal dominant condition characterized by the replacement of medullary bone by fibro-osseous lesions, predominantly in the bilateral maxillae and/or mandibles. The clinical presentation of cherubism can vary widely, from clinically undetectable to severe facial disfigurement. Although there are no established management guidelines for this condition, conservative management with observation is typically favored in most cases due to the possibility of spontaneous regression following puberty. In this article, we present three cases of moderate to severe cherubism managed with early surgical intervention utilizing curettage and osteotomy followed by bony repositioning. We aimed to show the feasibility and safety of this minimally invasive surgical technique in the management of moderate to severe cases of cherubism to provide improvement in patient quality of life, aesthetics, and function while also possibly mitigating the need for later reconstructive surgery.
Fine Needle Aspiration Cytologic Features of Cherubism
AbstractBACKGROUND: Cherubism is characterized by hereditary and intraosseous fibrous swellings of the jaws. It presents with bilateral mandibular and maxillary involvement in young individuals. Fine needle aspiration cytologic (FNAC) features have rarely been described in the literature; they include smears showing moderate cellularity with spindle cells mixed with multinucleated giant cells of osteoclast type. Therefore, giant cell containing soft tissue and bone lesions are considered in the differential diagnosis. CASE: A 13-year-old girl presented with bilateral symmetrical mandibular enlargement and was diagnosed as having cherubism on FNAC. CONCLUSION: We describe the cytomorphologic features of cherubism along with its differential diagnosis on cytology and emphasize that with clinicoradiologic correlation, a specific diagnosis can be offered for a definitive therapeutic approach.
AbstractDespite the exceptions, cherubism is a clinically well-characterized disease. In cases of a suspicion of cherubism, radiographic examination is essential since the clinical presentation, the location and distribution of the lesions may define the diagnosis. Histopathological examination is complementary. Nowadays, genetic tests should be used for final diagnosis of cherubism.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
